Kiyosue, Arihiro

Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: the PIONEER 8 trial.

Zinman, B., Aroda, V. R., Buse, J. B., Cariou, B., Harris, S. B., Hoff, S. T., Pedersen, K. B., Tarp-Johansen, M. J., Araki, E., PIONEER 8 Investigators, et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 300

Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial

Yamada, Y., Katagiri, H., Hamamoto, Y., Deenadayalan, S., Navarria, A., Nishijima, K., Seino, Y., Fukushima, Y., Hamamoto, Y., Hisatomi, A., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 228

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 210

Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial

Kaku, K., Yamada, Y., Watada, H., Abiko, A., Nishida, T., Zacho, J., & Kiyosue, A. (2018) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 132

A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk

Kiyosue, A., Honarpour, N., Kurtz, C., Xue, A., Wasserman, S. M., & Hirayama, A. (2016) · The American Journal of Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 114

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15

Yamashita, S., Kiyosue, A., Maheux, P., Mena-Madrazo, J., Lesogor, A., Shao, Q., Tamaki, Y., Nakamura, H., Akahori, M., & Kajinami, K. (2024) · Journal of Atherosclerosis and Thrombosis

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 26

Cost-Effectiveness of Statin Plus Eicosapentaenoic Acid Combination Therapy for Cardiovascular Disease Prevention in Japanese Patients With Hypercholesterolemia ― An Analysis Based on the Japan Eicosapentaenoic Acid Lipid Intervention Study (JELIS) ―

Kodera, S., Morita, H., Kiyosue, A., Ando, J., & Komuro, I. (2018) · Circulation Journal

Health Systems, Economic Evaluations, Quality of LifeLipoproteins and Cardiovascular Health

Cited by 21

Safety and efficacy of the combination of the glucagon‐like peptide‐1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post‐hoc analysis of a randomized, 52‐week, open‐label, parallel‐group trial

Kiyosue, A., Seino, Y., Nishijima, K., Bosch‐Traberg, H., & Kaku, K. (2018) · Journal of Diabetes Investigation

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 5